Table 3.
Progression-free survival, time to progression, and overall survival according to demographic, clinical, and genetic factors.
| Variable | Progression-Free Survival | Time to Progression | Overall Survival | ||||
|---|---|---|---|---|---|---|---|
| Median (days) |
p HR (95% CI) |
Median (days) |
p HR (95%CI) |
Median (days) |
p HR (95% CI) |
||
| Sex | Male Female |
41 122 |
0.7841 0.93 (0.56–1.55) 1.07(0.64–1.78) |
164 60 |
0.7789 0.93(0.56–1.55) 1.07(0.64–1.78) |
321 407 |
0.5208 1.18 (0.72–1.94) 0.84 (0.51–1.39) |
| Age [years] | ≥66.5 <66.5 |
82 122 |
0.1053 1.40 (0.91–2.16) 0.71 (0.46–1.09) |
117 177 |
0.1059 1.41 (0.92–2.16) 0.71 (0.46–1.09) |
236 407 |
0.0577 1.50 (0.97–2.31) 0.67 (0.43–1.03) |
| Disease stage | III IV |
198 61 |
<0.0010 * 0.38 (0.25–0.58) 2.64 (1.73–4.02) |
222 92 |
<0.0010 * 0.38 (0.25–0.59) 2.60 (1.71–3.96) |
502 233 |
0.0018 * 0.50 (0.33–0.77) 1.99 (1.30–3.04) |
| Performance status (ECOG score) | 0 1 and 2 |
182 105 |
0.7049 0.86 (0.42–1.79) 1.16 (0.56–2.40) |
190 139 |
0.8071 0.91 (0.43–1.91) 1.10 (0.52–2.31) |
438 282 |
0.2111 0.61 (0.32–1.17) 1.63 (0.86–3.09) |
| Smoking status | Smoker Non-smoker |
122 36 |
0.6115 0.79 (0.29–2.16) 1.26 (0.46–3.41) |
149 51 |
0.6865 0.83 (0.31–2.22) 1.20 (0.45–3.20) |
332 412 |
0.3914 1.48 (0.69–3.17) 0.68 (0.32–1.45) |
| Pack years | <45 ≥45 |
122 89 |
0.0374 * 0.65 (0.43–0.99) 1.53 (1.00–2.34) |
177 115 |
0.0292 * 0.64 (0.52–0.97) 1.57 (1.02–2.40) |
337 321 |
0.2597 0.78 (0.51–1.20) 1.27 (0.83–1.95) |
| 1st line chemotherapy(I) | Cisplatin + Pemetrexed Other |
841 22 |
0.0263 * 1.67 (0.96–2.91) 0.60 (0.34–1.04) |
92 151 |
0.0185 * 1.74 (0.99–3.03) 0.57 (0.33–1.01) |
233 337 |
0.0716 1.55 (0.89–2.67) 0.65 (0.37–1.20) |
| PN Other |
133 83 |
0.0770 0.69 (0.44–1.08) 1.45 (0.92–2.28) |
167 117 |
0.1250 0.72 (0.46–1.13) 1.39 (0.88–2.18) |
332 321 |
0.9832 0.99 (0.64–1.54) 1.00 (0.65–1.55) |
|
| PG Other |
76 122 |
0.9582 1.02 (0.54–1.93) 0.98 (0.52–1.86) |
135 164 |
0.6860 0.88 (0.48–1.61) 1.14 (0.62–2.09) |
355 337 |
0.5481 0.82 (0.44–1.52) 1.22 (0.66–2.27) |
|
| Number of cycles | ≤3 >3 |
41 213 |
<0.0001 * 2.31 (1.46–3.64) 0.43 (0.27–0.68) |
60 237 |
0.0002 * 2.15 (1.37–3.38) 0.46 (0.29–0.73) |
143 502 |
0.0094 * 1.74 (1.11–2.71) 0.58 (0.37–0.90) |
| Distant metastases (any) | No Yes |
213 61 |
0.0005 * 0.41 (0.26–0.66) 2.42 (1.51–3.88) |
237 92 |
0.0004 * 0.40 (0.25–0.65) 2.48 (1.55–3.97) |
542 224 |
0.0019 * 0.44 (0.27–0.71) 2.25 (1.39–3.62) |
| Distant metastases (CNS) | No Yes |
198 41 |
<0.0001 * 0.21 (0.06–0.70) 4.69 (1.43–15.36) |
222 60 |
0.0001 * 0.28 (0.09–0.81) 3.54 (1.23–10.16) |
542 99 |
<0.0001 * 0.24 (0.07–0.78) 4.24 (1.28–14.05) |
| Distant metastases (Bones) | No Yes |
198 47 |
0.0014 * 0.43 (0.22–0.83) 2.34 (1.20–4.56) |
222 70 |
0.0025 * 0.44 (0.23–0.86) 2.25 (1.17–4.35) |
542 185 |
0.0041 * 0.46 (0.23–0.89) 2.19 (1.22–4.28) |
| Distant metastases (second lung) | No Yes |
198 69 |
0.0057 * 0.46 (0.23–0.93) 2.19 (1.08–4.43) |
222 92 |
0.0075 * 0.46 (0.23–0.94) 2.15 (1.07–4.34) |
542 159 |
0.0304 * 0.53 (0.26–1.06) 1.89 (0.95–3.79) |
| Distant metastases (andrenal glands) | No Yes |
198 40 |
<0.0001 * 0.15 (0.02–0.90) 6.73 (1.11–40.75) |
222 58 |
<0.0001 * 0.13 (0.02–0.89) 7.38 (1.13–48.39) |
542 114 |
0.0194 * 0.40 (0.13–1.27) 2.51 (0.79–7.96) |
| Distant metastases (liver) | No Yes |
198 61 |
<0.0001 * 0.18 (0.03–0.94) 5.49 (1.07–28.25) |
222 70 |
<0.0001 * 0.16 (0.03–0.91) 6.33 (1.10–36.40) |
542 137 |
0.2408 1.73 (0.54–5.58) 0.57 (0.18–1.86) |
| Distant metastases (distant lymph nodes) | No Yes |
198 69 |
0.0134 * 0.47 (0.22–1.02) 2.11 (0.98–4.54) |
222 127 |
0.0194 * 0.49 (0.23–1.04) 2.04 (0.96–4.36) |
542 249 |
0.0290 * 0.50 (0.23–1.09) 1.99 (0.91–4.33) |
| Weight [kg] | ≥74 kg <74 kg |
122 92 |
0.9349 0.98 (0.65–1.50) 1.02 (0.67–1.55) |
177 142 |
0.9347 0.98 (0.65–1.50) 1.02 (0.67–1.55) |
339 274 |
0.4725 0.85 (0.56–1.31) 1.17 (0.76–1.79) |
| BMI [kg/m2] | ≥24.91 <24.91 |
122 89 |
0.7448 1.07 (0.70–1.63) 0.93 (0.61–1.42) |
142 151 |
0.6772 1.09 (0.72–1.66) 0.92 (0.60–1.39) |
339 274 |
0.8440 0.96 (0.63–1.47) 1.04 (0.68–1.60) |
| Wieght loss [%] | <9.84 ≥9.84 |
131 47 |
0.4782 0.85 (0.53–1.36) 1.17 (0.73–1.87) |
181 78 |
0.5073 0.86 (0.54–1.37) 1.16 (0.73–1.86) |
438 168 |
0.0833 0.67 (0.41–1.11) 1.48 (0.90–2.45) |
| Time from diagnosis to treatment [days] | ≥17 <17 |
92 122 |
0.0254 * 1.58 (1.03–2.42) 0.64 (0.41–0.97) |
149 145 |
0.1736 1.33 (0.87–2.02) 0.75 (0.49–1.15) |
339 282 |
0.8289 0.95 (0.62–1.46) 1.05 (0.68–1.60) |
| Occupational exposure | No Yes |
95 105 |
0.6952 1.13 (0.62–2.08) 0.88 (0.48–1.62) |
139 164 |
0.7607 1.10 (0.60–2.03) 0.91 (0.49–1.67) |
282 350 |
0.9557 1.02 (0.54–1.91) 0.98 (0.52–1.84) |
| Family history of any cancer | No Yes |
152.00 95.00 |
0.8875 0.97 (0.64–1.48) 1.03 (0.68–1.57) |
190.00 134.00 |
0.8701 0.96 (0.63–1.47) 1.03 (0.68–1.58) |
282.00 332.00 |
0.5718 1.13 (0.74–1.73) 0.88 (0.58–1.36) |
| Family history of lung cancer | No Yes |
107.00 92.00 |
0.9243 1.03 (0.55–1.92) 0.97 (0.52–1.81) |
135.00 132.00 |
0.8842 1.05 (0.56–1.95) 0.95 (0.51–1.78) |
438.00 168.00 |
0.5715 0.84 (0.45–1.56) 1.19 (0.64–2.22) |
| Histopathology | SCC AC and NOS |
95.00 137.00 |
0.9491 0.98 (0.58–1.66) 1.02 (0.60–1.72) |
139.00 167.00 |
0.8259 0.94 (0.58–1.60) 1.06 (0.63–1.79) |
389.00 337.00 |
0.8306 0.94 (0.54–1.64) 1.06 (0.61–1.85) |
| AC SCC and NOS |
137.00 89.00 |
0.6508 0.89 (0.53–1.49) 1.13 (0.67–1.89) |
167.00 135.00 |
0.7572 0.92 (0.55–1.55) 1.08 (0.64–1.83) |
337.00 389.00 |
0.7346 1.10 (0.63–1.92) 0.91 (0.52–1.59) |
|
| BIRC5 (rs8073069) | CC GG and CG |
61.00 122.00 |
0.1027 0.55 (0.30–1.01) 1.83 (0.99–3.36) |
219.00 145.00 |
0.0871 0.52 (0.29–0.96) 1.90(1.04–3.47) |
438.00 321.00 |
0.2093 0.59 (0.30–1.17) 1.68 (0.86–3.28) |
| GG CC and CG |
91.00 137.00 |
0.2788 1.26 (0.81–1.94) 0.79 (0.52–1.23) |
127.00 177.00 |
0.3392 1.23 (0.80–1.89) 0.81 (0.53–1.25) |
236.00 472.00 |
0.0066 * 1.77 (1.13–2.78) 0.56 (0.36–0.89) |
|
| CG CC and CG |
137.00 89.00 |
0.9644 1.01(0.66–1.54) 0.99 (0.65–1.51) |
164.00 127.00 |
0.8070 1.05 (0.69–1.60) 0.94 (0.62–1.45) |
473.00 242.00 |
0.0788 0.68 (0.45–1.05) 1.46 (0.95–2.24) |
|
Abbreviations: AC—adenocarcinoma; BMI—body mass index; Cis—Cisplatin; Pem—Pemetrexed; PG—Cisplatin + Gemcitabine; PN—Cisplatin + Vinorelbine; SCC—squamous cell carcinoma. *-statistically significant. In some cases (n = 12 for PFS and TTP; n = 9 for OS) reliable determination of the survival time was not possible (too short follow-up—discontinuation of treatment prior to assessment time because of poor tolerance, failure to appear at the next appointment, or any and all contact with a patient was lost).